As of June 21, 2025, Chiasma Inc (CHMA) reports a Current Ratio of 9.19.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Chiasma Inc's Current Ratio
Over recent years, Chiasma Inc's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2020-12-31 | 9.19 |
| 2019-12-31 | 8.45 |
| 2018-12-31 | 2.17 |
| 2017-12-31 | 10.25 |
| 2016-12-31 | 11.32 |
This slight upward trend highlights how Chiasma Inc manages its short-term assets and liabilities over time.
Comparing Chiasma Inc's Current Ratio to Peers
To better understand Chiasma Inc's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Chiasma Inc (CHMA) | 9.19 |
| scPharmaceuticals Inc (SCPH) | 7.12 |
| Odonate Therapeutics Inc (ODT) | 5.90 |
| Onconova Therapeutics Inc (ONTX) | 4.91 |
| Cardiol Therapeutics Inc (CRDL.TO) | 4.52 |
| Strongbridge Biopharma plc (SBBP) | 4.38 |
Compared to its competitors, Chiasma Inc's Current Ratio is higher than all peers, indicating strong short-term financial flexibility but potentially excess cash that could be invested.